Result 1 - 10 of total 20
Chest
| Keywords | covid19 |
|---|---|
| Publisher | Elsevier; PMC |
| Document type | Article ; Online |
| DOI | 10.1016/j.chest.2020.08.671 |
| Database | COVID19 |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
2018 Volume 34, Issue 2, Page(s) 250–256
Abstract: Background: Diabetes mellitus (DM) is estimated to affect 9% of Americans and is associated with significant morbidity, mortality, and increased healthcare costs.: Methods: A retrospective review of a home enteral nutrition (HEN) database of patients ...
| Abstract | Background: Diabetes mellitus (DM) is estimated to affect 9% of Americans and is associated with significant morbidity, mortality, and increased healthcare costs. Methods: A retrospective review of a home enteral nutrition (HEN) database of patients seen between March 1, 2004, and April 31, 2014, at our institution was conducted to identify HEN patients who had a diagnosis of DM or were diagnosed within the acute period (4 months) of starting HEN therapy. Results: 174 (3.7%) of 4682 patients in the HEN program had DM. HEN was provided through a gastrostomy tube in 82 patients and through a jejunostomy tube in 92 patients. At 3 months, data were available for 42 gastrostomy patients; 44% had a change in DM management, with 60% undergoing a change to insulin. Similarly, 34 patients with jejunostomy had data available, with 41% undergoing change in medication and 93% being changed to insulin therapy. For patients with available glycated hemogloblin values, at 3 months the gastrostomy patients noted a decrease of 0.5% (7.3% ± 1.1% to 6.8% ± 0.7%, not significant) and the jejunostomy patients noted a decrease of 0.4% (6.9% ± 0.9% to 6.5% ± 1.1%, P = .06). Conclusions: Overall, our results suggest that closer follow-up and laboratory assessment are necessary for management of HEN patients with DM. In those with data available, glycemic control can be maintained in patients receiving HEN with appropriate adjustment of DM management and focus on ensuring that patients are not overfed. |
|---|---|
| MeSH term(s) | Aged ; Diabetes Mellitus/therapy ; Enteral Nutrition ; Female ; Glycated Hemoglobin A/analysis ; Home Care Services ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use ; Male ; Middle Aged |
| Chemical Substances | Glycated Hemoglobin A ; Hypoglycemic Agents ; Insulin |
| Language | English |
| Publishing date | 2018-07-13 |
| Publishing country | United States |
| Document type | Journal Article ; Review |
| ZDB-ID | 645074-x |
| ISSN | 1941-2452 ; 0884-5336 |
| ISSN (online) | 1941-2452 |
| ISSN | 0884-5336 |
| DOI | 10.1002/ncp.10104 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2451: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Nutrition in clinical practice. 2019 Apr., v. 34, no. 2
2019
Abstract: BACKGROUND: Diabetes mellitus (DM) is estimated to affect 9% of Americans and is associated with significant morbidity, mortality, and increased healthcare costs. METHODS: A retrospective review of a home enteral nutrition (HEN) database of patients seen ...
| Abstract | BACKGROUND: Diabetes mellitus (DM) is estimated to affect 9% of Americans and is associated with significant morbidity, mortality, and increased healthcare costs. METHODS: A retrospective review of a home enteral nutrition (HEN) database of patients seen between March 1, 2004, and April 31, 2014, at our institution was conducted to identify HEN patients who had a diagnosis of DM or were diagnosed within the acute period (4 months) of starting HEN therapy. RESULTS: 174 (3.7%) of 4682 patients in the HEN program had DM. HEN was provided through a gastrostomy tube in 82 patients and through a jejunostomy tube in 92 patients. At 3 months, data were available for 42 gastrostomy patients; 44% had a change in DM management, with 60% undergoing a change to insulin. Similarly, 34 patients with jejunostomy had data available, with 41% undergoing change in medication and 93% being changed to insulin therapy. For patients with available glycated hemogloblin values, at 3 months the gastrostomy patients noted a decrease of 0.5% (7.3% ± 1.1% to 6.8% ± 0.7%, not significant) and the jejunostomy patients noted a decrease of 0.4% (6.9% ± 0.9% to 6.5% ± 1.1%, P = .06). Conclusions: Overall, our results suggest that closer follow‐up and laboratory assessment are necessary for management of HEN patients with DM. In those with data available, glycemic control can be maintained in patients receiving HEN with appropriate adjustment of DM management and focus on ensuring that patients are not overfed. |
|---|---|
| Keywords | databases ; diabetes mellitus ; enteral feeding ; glycemic control ; insulin ; insulin replacement therapy ; morbidity ; mortality |
| Language | English |
| Dates of publication | 2019-04 |
| Size | p. 250-256. |
| Publishing place | John Wiley & Sons, Ltd |
| Document type | Article |
| Note | JOURNAL ARTICLE |
| ZDB-ID | 645074-x |
| ISSN | 1941-2452 ; 0884-5336 |
| ISSN (online) | 1941-2452 |
| ISSN | 0884-5336 |
| DOI | 10.1002/ncp.10104 |
| Database | NAL-Catalogue (AGRICOLA) |
| Zs.A 2451: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Therapeutics and clinical risk management
2015 Volume 11, Page(s) 1663–1674
Abstract: Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%-7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease ... ...
| Abstract | Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%-7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need for better therapies. Over the past few years, several novel agents with promising activity and unique mechanisms of action have been deemed effective in MCL. Bortezomib is a reversible proteasome inhibitor, approved as a single agent for patients with relapsed/refractory MCL who have received at least one prior line of therapy. Addition of bortezomib to chemoimmunotherapies has demonstrated good tolerability and superior efficacy, both in the upfront and salvage settings, and recently one such combination of bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone was approved as a frontline regimen in untreated patients with MCL. This review examines the role of bortezomib in a multitude of clinical settings and ongoing clinical trials designed to optimize its integration in the current treatment paradigms of MCL. |
|---|---|
| Language | English |
| Publishing date | 2015-11-06 |
| Publishing country | New Zealand |
| Document type | Journal Article ; Review |
| ZDB-ID | 2186560-7 |
| ISSN | 1178-203X ; 1176-6336 |
| ISSN (online) | 1178-203X |
| ISSN | 1176-6336 |
| DOI | 10.2147/TCRM.S72943 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 6067: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
American journal of hematology
2023 Volume 98, Issue 3, Page(s) 432–439
Abstract: Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, that predominately affects the elderly. We report the outcomes of young WM patients, evaluated over five decades, compared to their older counterparts, matched for the time of diagnosis. ... ...
| Abstract | Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, that predominately affects the elderly. We report the outcomes of young WM patients, evaluated over five decades, compared to their older counterparts, matched for the time of diagnosis. Between January 1, 1960 and October 31, 2013, 140 (11.8%) WM patients were ≤50 years of age at diagnosis in our database, and their estimated 10-year overall survival (OS) was 74%, with death attributable to WM in a higher proportion of patients compared to their older (≥65 years) counterparts (91% vs. 58%, p = .0001). Young patients were grouped into three cohorts based on the timing of the initiation of therapy: Group 1 (1960-1977, n = 12), Group 2 (1978-1995, n = 48), and Group 3 (1996-2013, n = 74). Among young patients, there was no disease-specific survival (DSS) difference across the three periods, [median DSS at 13 years (95% CI 5-23), 16 years (95% CI 14-22), and 15 years (95% CI 10-NR; p = .41), respectively]. However, DSS for the older cohort incrementally improved (Group 1, median 5.2 years, Group 2: 9.6 years, Group 3: 12 years; p = .05) over these periods. The estimated average years-of-life lost for the young cohort was 11.2 years from diagnosis, based on the expected survival for a normal age- and sex-matched population. Despite a protracted disease course, nearly all young patients succumb to their disease. In contrast to the improved survival of the elderly patient population, the evolving treatment strategies in WM have not impacted the outcome of young patients; however, the impact of Bruton tyrosine kinase inhibitors on this unique patient population remains to be determined. |
|---|---|
| MeSH term(s) | Humans ; Aged ; Waldenstrom Macroglobulinemia/drug therapy ; Waldenstrom Macroglobulinemia/diagnosis ; Disease Progression |
| Language | English |
| Publishing date | 2023-01-01 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 196767-8 |
| ISSN | 1096-8652 ; 0361-8609 |
| ISSN (online) | 1096-8652 |
| ISSN | 0361-8609 |
| DOI | 10.1002/ajh.26807 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 1251: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2015 Volume 29, Issue 5, Page(s) 301–319
Abstract: Waldenström macroglobulinemia (WM) is a distinct hematologic malignancy characterized by a lymphoplasmacytic bone marrow infiltration and the presence of immunoglobulin (Ig)M monoclonal protein. Patients typically present at an advanced age, and a ... ...
| Abstract | Waldenström macroglobulinemia (WM) is a distinct hematologic malignancy characterized by a lymphoplasmacytic bone marrow infiltration and the presence of immunoglobulin (Ig)M monoclonal protein. Patients typically present at an advanced age, and a substantial proportion are asymptomatic at diagnosis. A unifying diagnosis of WM may be missed by an unsuspecting hematologist, as symptomatic patients present with a multitude of non-specific manifestations. Although constitutional and neuropathy-related symptoms predominate, concomitant IgM-induced hyperviscosity-associated features can provide useful diagnostic clues. There are specific indications for initiation of therapy. This review focuses on the most up-to-date management strategies of WM, in addition to highlighting the recent discoveries of MYD88 and CXCR4 mutations that have shed unprecedented light on the complex signaling pathways, and opened avenues for novel therapeutic targeting. Although WM remains incurable, with the rapid emergence and integration of effective novel therapies, its clinical course appears poised to improve in the foreseeable future. |
|---|---|
| MeSH term(s) | Humans ; Waldenstrom Macroglobulinemia |
| Language | English |
| Publishing date | 2015-09 |
| Publishing country | England |
| Document type | Journal Article ; Review |
| ZDB-ID | 639015-8 |
| ISSN | 1532-1681 ; 0268-960X |
| ISSN (online) | 1532-1681 |
| ISSN | 0268-960X |
| DOI | 10.1016/j.blre.2015.03.001 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2207: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2017 Volume 32, Issue 2, Page(s) 201–205
Abstract: Background: Long-term use of enteral nutrition (EN) continues to increase due to significant noted benefits. Patients also continue to express significant desire to pursue holistic and organic diets. Despite this, many nutrition providers are not well ... ...
| Abstract | Background: Long-term use of enteral nutrition (EN) continues to increase due to significant noted benefits. Patients also continue to express significant desire to pursue holistic and organic diets. Despite this, many nutrition providers are not well versed in assisting patients with blenderized tube feeding (BTF), and prevalence of its use is unknown. Methods: A validated survey was administered to Oley Foundation members or individuals with access to the Oley website to assess the prevalence of BTF. Results: A total of 216 participants took the survey, of whom 125 (57.8%) were pediatric patients with a mean age of 5.4 ± 3.5 years and 91 (42.2%) were adults with a mean age of 51.7 ± 19.5 years. Of pediatric patients, 112 (89.6%) used BTF for an average of 71% of their total daily nutrition intake; 93 (83%) reported that BTF comprised >50% of their daily EN, 12 (10.7%) reported it comprised 25%-50% of their daily enteral intake, and 7 (6.3%) reported BTF comprised < 25% of their daily intake. In the adult population, 60 (65.9%) used BTF for an average of 56% of total daily nutrition intake; 41 (68.4%) reported BTF comprised >50% of their daily nutrition intake, 11 (18.3%) reported it compromised 25%-50%, and 8 (13.3%) reported BTF comprised <25% of their daily intake. Conclusions: Most of the pediatric and adult patients surveyed use BTF as some portion of their enteral intake, making it essential that clinicians expand their knowledge related to BTF to appropriately care for this patient population. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Child ; Child, Preschool ; Cross-Sectional Studies ; Enteral Nutrition/methods ; Female ; Food, Formulated ; Home Care Services ; Humans ; Infant ; Male ; Middle Aged ; Nutritional Status ; Nutritionists ; Reproducibility of Results ; Surveys and Questionnaires |
| Language | English |
| Publishing date | 2017-04 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 645074-x |
| ISSN | 1941-2452 ; 0884-5336 |
| ISSN (online) | 1941-2452 |
| ISSN | 0884-5336 |
| DOI | 10.1177/0884533616662992 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2451: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2014 Volume 124, Issue 6, Page(s) 873–881
Abstract: Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal bone marrow disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and potential for malignant transformation. Lower/intermediate-risk MDSs are associated ... ...
| Abstract | Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal bone marrow disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and potential for malignant transformation. Lower/intermediate-risk MDSs are associated with longer survival and high red blood cell (RBC) transfusion requirements resulting in secondary iron overload. Recent data suggest that markers of iron overload portend a relatively poor prognosis, and retrospective analysis demonstrates that iron chelation therapy is associated with prolonged survival in transfusion-dependent MDS patients. New data provide concrete evidence of iron's adverse effects on erythroid precursors in vitro and in vivo. Renewed interest in the iron field was heralded by the discovery of hepcidin, the main serum peptide hormone negative regulator of body iron. Evidence from β-thalassemia suggests that regulation of hepcidin by erythropoiesis dominates regulation by iron. Because iron overload develops in some MDS patients who do not require RBC transfusions, the suppressive effect of ineffective erythropoiesis on hepcidin may also play a role in iron overload. We anticipate that additional novel tools for measuring iron overload and a molecular-mechanism-driven description of MDS subtypes will provide a deeper understanding of how iron metabolism and erythropoiesis intersect in MDSs and improve clinical management of this patient population. |
|---|---|
| MeSH term(s) | Chelation Therapy ; Erythrocyte Transfusion/adverse effects ; Erythrocytes/metabolism ; Erythropoiesis ; Hepcidins/blood ; Humans ; Iron/blood ; Iron/metabolism ; Iron Chelating Agents/therapeutic use ; Iron Overload/blood ; Iron Overload/drug therapy ; Iron Overload/etiology ; Models, Biological ; Myelodysplastic Syndromes/blood ; Myelodysplastic Syndromes/complications ; Myelodysplastic Syndromes/therapy ; Risk Factors |
| Chemical Substances | Hepcidins ; Iron Chelating Agents ; Iron (E1UOL152H7) |
| Language | English |
| Publishing date | 2014-06-12 |
| Publishing country | United States |
| Document type | Journal Article ; Review |
| ZDB-ID | 80069-7 |
| ISSN | 1528-0020 ; 0006-4971 |
| ISSN (online) | 1528-0020 |
| ISSN | 0006-4971 |
| DOI | 10.1182/blood-2014-03-563221 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Uh III Zs.140: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 364: Show issues |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Nutrition in clinical practice. , v. 32, no. 2
2017
Abstract: Background: Long-term use of enteral nutrition (EN) continues to increase due to significant noted benefits. Patients also continue to express significant desire to pursue holistic and organic diets. Despite this, many nutrition providers are not well ... ...
| Abstract | Background: Long-term use of enteral nutrition (EN) continues to increase due to significant noted benefits. Patients also continue to express significant desire to pursue holistic and organic diets. Despite this, many nutrition providers are not well versed in assisting patients with blenderized tube feeding (BTF), and prevalence of its use is unknown. Methods: A validated survey was administered to Oley Foundation members or individuals with access to the Oley website to assess the prevalence of BTF. Results: A total of 216 participants took the survey, of whom 125 (57.8%) were pediatric patients with a mean age of 5.4 ± 3.5 years and 91 (42.2%) were adults with a mean age of 51.7 ± 19.5 years. Of pediatric patients, 112 (89.6%) used BTF for an average of 71% of their total daily nutrition intake; 93 (83%) reported that BTF comprised >50% of their daily EN, 12 (10.7%) reported it comprised 25%–50% of their daily enteral intake, and 7 (6.3%) reported BTF comprised < 25% of their daily intake. In the adult population, 60 (65.9%) used BTF for an average of 56% of total daily nutrition intake; 41 (68.4%) reported BTF comprised >50% of their daily nutrition intake, 11 (18.3%) reported it compromised 25%–50%, and 8 (13.3%) reported BTF comprised <25% of their daily intake. Conclusions: Most of the pediatric and adult patients surveyed use BTF as some portion of their enteral intake, making it essential that clinicians expand their knowledge related to BTF to appropriately care for this patient population. |
|---|---|
| Keywords | adults ; diet ; Internet ; patients ; surveys ; tube feeding |
| Language | English |
| Dates of publication | 2017-04 |
| Size | p. 201-205. |
| Publishing place | SAGE Publications |
| Document type | Article |
| ZDB-ID | 645074-x |
| ISSN | 1941-2452 ; 0884-5336 |
| ISSN (online) | 1941-2452 |
| ISSN | 0884-5336 |
| DOI | 10.1177/0884533616662992 |
| Database | NAL-Catalogue (AGRICOLA) |
| Zs.A 2451: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Clinical nutrition (Edinburgh, Scotland)
2017 Volume 37, Issue 4, Page(s) 1181–1185
Abstract: Background & aims: Ethanol lock therapy (ELT) has been shown to reduce the rate of catheter-related bloodstream infection (CRBSI) in high-risk home parenteral nutrition (HPN) patients. The aim of this study was to determine whether ELT therapy for all ... ...
| Abstract | Background & aims: Ethanol lock therapy (ELT) has been shown to reduce the rate of catheter-related bloodstream infection (CRBSI) in high-risk home parenteral nutrition (HPN) patients. The aim of this study was to determine whether ELT therapy for all patients newly started on HPN would reduce the incidence of CRBSI. Methods: This study was a prospective, double-blind, randomized controlled trial that was carried out from July 2014 to April 2016. The study participants were patients newly started on HPN, and they were randomly assigned to either treatment with ELT or our current standard of care with saline heparin locks. The primary outcome was occurrence of CRBSI. Results: Thirty eight patients that were newly started on HPN were randomized to either treatment with ELT (n = 18) or to our current standard of care with heparin locks (n = 20). Four patients in the ELT group and one patient in the control arm had a CRBSI (p = 0.17). No significant adverse side effects were noted during the study. Conclusions: This study did not show improvement in the rate of CRBSI with ELT in all patients started on HPN. ELT therapy may be most helpful to reduce in CRBSI in high-risk HPN patients, but further studies with a randomized control trial design of high-risk patients are needed to further clarify this important issue in HPN patients. The study was registered at clinicaltrials.gov prior to patient enrollment (NCT02227329). |
|---|---|
| MeSH term(s) | Adult ; Aged ; Bacteremia/prevention & control ; Catheter-Related Infections/prevention & control ; Catheterization, Central Venous/adverse effects ; Catheterization, Central Venous/methods ; Central Venous Catheters/adverse effects ; Double-Blind Method ; Ethanol/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Parenteral Nutrition, Home/adverse effects ; Parenteral Nutrition, Home/methods ; Prospective Studies |
| Chemical Substances | Ethanol (3K9958V90M) |
| Language | English |
| Publishing date | 2017-05-17 |
| Publishing country | England |
| Document type | Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 604812-2 |
| ISSN | 1532-1983 ; 0261-5614 |
| ISSN (online) | 1532-1983 |
| ISSN | 0261-5614 |
| DOI | 10.1016/j.clnu.2017.05.009 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 1774: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.